Innocoll AG (INNL) Cut to “Hold” at Zacks Investment Research
According to Zacks, “Innocoll Holdings develops and manufactures pharmaceutical products and medical devices through its proprietary collagen-based technologies. The company’s product include CollaGUARD(Ex-US), CollatampG(R), Septocoll(R), RegenePro(R), Collieva(R), CollaCare(R), Collexa(R) and Zorpreva(TM). It operates primarily in Asia, Australia, Canada, Europe, Latin America, the Middle East and the United States. Innocoll AG, formerly known as Innocoll GmbH, is headquartered in Athlone, Ireland. “
Separately, FBR & Co initiated coverage on Innocoll AG in a research note on Thursday, June 30th. They issued an “outperform” rating and a $18.00 price objective on the stock.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/18/innocoll-ag-innl-cut-to-hold-at-zacks-investment-research.html
Shares of Innocoll AG (NASDAQ:INNL) traded down 0.82% during midday trading on Tuesday, reaching $6.03. The company’s stock had a trading volume of 150,859 shares. The stock has a 50 day moving average price of $6.03 and a 200-day moving average price of $6.84. Innocoll AG has a 52-week low of $4.57 and a 52-week high of $13.72. The company’s market capitalization is $146.85 million.
Innocoll AG (NASDAQ:INNL) last issued its quarterly earnings data on Wednesday, August 17th. The specialty pharmaceutical company reported ($0.62) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.73) by $0.11. Innocoll AG had a negative return on equity of 1,226.28% and a negative net margin of 1,139.95%. The business had revenue of $1.30 million for the quarter, compared to the consensus estimate of $1.04 million. Equities research analysts expect that Innocoll AG will post ($2.41) EPS for the current year.
About Innocoll AG
Innocoll Holdings plc is a commercial-stage specialty pharmaceutical and medical device company with late stage development programs targeting areas of significant unmet medical need. The Company utilizes its collagen-based technology platform to develop biodegradable and fully bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Innocoll AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innocoll AG and related companies with MarketBeat.com's FREE daily email newsletter.